[go: up one dir, main page]

WO2003048361A3 - P55pik - Google Patents

P55pik Download PDF

Info

Publication number
WO2003048361A3
WO2003048361A3 PCT/GB2002/005547 GB0205547W WO03048361A3 WO 2003048361 A3 WO2003048361 A3 WO 2003048361A3 GB 0205547 W GB0205547 W GB 0205547W WO 03048361 A3 WO03048361 A3 WO 03048361A3
Authority
WO
WIPO (PCT)
Prior art keywords
p55pik
polypeptide
iii
nucleic acid
set out
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2002/005547
Other languages
English (en)
Other versions
WO2003048361A2 (fr
Inventor
Ian Hayes
Thomas Cotter
Finbarr Murphy
Liam Seery
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EiRx Therapeutics Ltd
Original Assignee
EiRx Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0129377A external-priority patent/GB0129377D0/en
Priority claimed from GB0200831A external-priority patent/GB0200831D0/en
Application filed by EiRx Therapeutics Ltd filed Critical EiRx Therapeutics Ltd
Priority to AU2002347368A priority Critical patent/AU2002347368A1/en
Publication of WO2003048361A2 publication Critical patent/WO2003048361A2/fr
Publication of WO2003048361A3 publication Critical patent/WO2003048361A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01137—Phosphatidylinositol 3-kinase (2.7.1.137)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un procédé permettant de détecter l'apoptose dans une cellule et consistant entre autres à détecter une altération d'un quelconque élément suivant : i) un polypeptide de p55PIK présentant une séquence d'acides aminés telle que représentée par SEQ ID NO:1 ; ii) un polypeptide présentant au moins 80 % d'homologie avec i) ; iii) un acide nucléique codant pour un polypeptide présentant la séquence établie en i) ou en ii) ; iv) un acide nucléique s'hydridant avec la séquence établie en iii) lorsqu'il est soumis à des conditions rigoureuses ; ou v) le complément de iii) ou de iv). En conséquence, l'invention concerne un procédé permettant de moduler l'apoptose, par modulation de l'expression du gène p55PIK, et un procédé permettant d'identifier des gènes associés à l'expression du gène p55PIK et ainsi d'identifier d'autres gènes associés à l'apoptose. L'invention se rapporte en outre à une nouvelle séquence d'acides nucléiques codant pour la région promoteur de p55PIK.
PCT/GB2002/005547 2001-12-07 2002-12-06 P55pik Ceased WO2003048361A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002347368A AU2002347368A1 (en) 2001-12-07 2002-12-06 P55pik

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0129377.8 2001-12-07
GB0129377A GB0129377D0 (en) 2001-12-07 2001-12-07 p55PIK
GB0200831.6 2002-01-15
GB0200831A GB0200831D0 (en) 2002-01-15 2002-01-15 p55PIK

Publications (2)

Publication Number Publication Date
WO2003048361A2 WO2003048361A2 (fr) 2003-06-12
WO2003048361A3 true WO2003048361A3 (fr) 2004-03-18

Family

ID=26246851

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/005547 Ceased WO2003048361A2 (fr) 2001-12-07 2002-12-06 P55pik

Country Status (2)

Country Link
AU (1) AU2002347368A1 (fr)
WO (1) WO2003048361A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100090A (en) * 1999-06-25 2000-08-08 Isis Pharmaceuticals Inc. Antisense inhibition of PI3K p85 expression
US6165790A (en) * 1999-11-03 2000-12-26 Isis Pharmaceuticals Inc. Antisense modulation of PI3 kinase p55 gamma expression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100090A (en) * 1999-06-25 2000-08-08 Isis Pharmaceuticals Inc. Antisense inhibition of PI3K p85 expression
US6165790A (en) * 1999-11-03 2000-12-26 Isis Pharmaceuticals Inc. Antisense modulation of PI3 kinase p55 gamma expression

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BERNABÉ J C ET AL: "Sodium nitroprusside-induced mitochondrial apoptotic events in insulin-secreting RINm5F cells are associated with MAP kinases activation.", EXPERIMENTAL CELL RESEARCH. UNITED STATES 1 OCT 2001, vol. 269, no. 2, 1 October 2001 (2001-10-01), pages 222 - 229, XP002256953, ISSN: 0014-4827 *
DATABASE NCBI SNP [online] 28 June 2001 (2001-06-28), XP002256956, accession no. WWW.NCBI.NLM.NIH.GOV/SNP Database accession no. rs785468, ss3177819 *
DEY B R ET AL: "CLONING OF HUMAN P55GAMMA, A REGULATORY SUBUNIT OF PHOSPHATIDYLINOSITOL 3-KINASE, BY YEAST TWO-HYBRID LIBRARY SCREEN WITH THE INSULIN-LIKE GROWTH FACTOR-I RECEPTOR", GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, ELSEVIER SCIENCE PUBLISHERS, BARKING, GB, vol. 209, 1998, pages 175 - 183, XP002938192, ISSN: 0378-1119 *
INUKAI K ET AL: "The N-terminal 34 residues of the 55 kDa regulatory subunits of phosphoinositide 3-kinase interact with tubulin.", THE BIOCHEMICAL JOURNAL. ENGLAND 1 MAR 2000, vol. 346 Pt 2, 1 March 2000 (2000-03-01), pages 483 - 489, XP002256955, ISSN: 0264-6021 *
JOST M ET AL: "Epidermal growth factor receptor-dependent control of keratinocyte survival and Bcl-xL expression through a MEK-dependent pathway.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 2 MAR 2001, vol. 276, no. 9, 2 March 2001 (2001-03-02), pages 6320 - 6326, XP002256952, ISSN: 0021-9258 *
SHIN B C ET AL: "Multiple isoforms of the regulatory subunit for phosphatidylinositol 3-kinase (PI3-kinase) are expressed in neurons in the rat brain.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. UNITED STATES 19 MAY 1998, vol. 246, no. 2, 19 May 1998 (1998-05-19), pages 313 - 319, XP002256954, ISSN: 0006-291X *

Also Published As

Publication number Publication date
WO2003048361A2 (fr) 2003-06-12
AU2002347368A8 (en) 2003-06-17
AU2002347368A1 (en) 2003-06-17

Similar Documents

Publication Publication Date Title
ATE347591T1 (de) Thermostabile alpha-amylase
ZA967173B (en) Purified coprinus laccases and nucleic acids and encoding same
WO2004099228A3 (fr) Variantes de beta-glucosidases
CA2166685A1 (fr) Enzyme avec activite proteasique
EP0889133A3 (fr) Procédé de préparation de transglutaminase microbienne
CA2327266A1 (fr) Toxines pesticides et sequences nucleotidiques codant pour ces toxines
NZ311180A (en) Nucleotide sequence encoding a peptide having beta-xylosidase activity and use thereof
CA2252493A1 (fr) Gene de la .beta.-galactoside - .alpha. 2,6-sialyltransferase
CA2264962A1 (fr) Facteur de transcription regulant la voie de biosynthese du phenylpropanoide
AU6724794A (en) GRB3-3 gene, its variants and their uses
IL155940A0 (en) Promoters exhibiting endothelial cell specificity and method of using same
EP1476462A4 (fr) Nouvelle lipase fongique
WO2003048767A3 (fr) Elavl-1
AU5727099A (en) A 2,6-beta-d-fructan hydrolase enzyme and processes for using the enzyme
WO2003091384A3 (fr) Survivine
CA2301902A1 (fr) Nouvelle serine protease extracellulaire
WO2003048361A3 (fr) P55pik
WO2002081650A3 (fr) Sequences nucleotidiques regulatrices d'alcool oxydase 1 pour l'expression de genes heterologues dans une levure
WO2003050302A3 (fr) Tgnp
WO2003054010A3 (fr) Modulateurs 2 d'apoptose precoce a oxydoreduction associee (esram-2)
AU2001273977A1 (en) Novel nucleotide sequences coding for the glbo gene
WO2002010384A1 (fr) Genes codant des proteines capables de regenerer la luciferine, adn recombine et methode de production de proteines capables de regenerer la luciferine
EP1728859A4 (fr) Sequence capable d'accelerer l'expression genique a une temperature moderement faible
SE9801098D0 (sv) Receptors
EP0845536A3 (fr) Protéine à activité de l'acide éthylènediamine-N-N'-succinique: éthylènediamine lyase et ADN codant pour celle-ci

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP